Senior Group Leader and Head of CRUK Laboratories, Gurdon Institute
Stephen Jackson FRS, FMedSci is Cambridge University Professor of Biology, Head of CRUK Laboratories at the Gurdon Institute, and an Associate Faculty at the Sanger Institute. Stephen’s research has provided us with many principles by which cells respond to and repair DNA damage, and has indicated how DNA-repair dysfunction yields cancer and other diseases. Steve founded the companies KuDOS Pharmaceuticals (he was CSO 1997-2010) and MISSION Therapeutics (2010-date). Three KuDOS drugs are now in clinical trials by AstraZeneca. One of these, olaparib/Lynparza, was recently approved for market in the USA and EU for ovarian cancer, and is in late-phase trials for various other cancers.